Journal article
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.
Abstract
BACKGROUND: Both hyper- and hypokalemia increase cardiovascular risk. Modest hyperkalemia is common with angiotensin-converting enzyme inhibition. We studied post-hoc the association of an initial, on-treatment serum potassium measurement with subsequent cardiovascular outcomes over 4.5 years in 9297 individuals at high cardiovascular risk, randomized to an ACE inhibitor or to placebo.
METHODS: Post-hoc analysis of cardiovascular outcomes, as …
Authors
Mann JFE; Yi Q-L; Sleight P; Dagenais GR; Gerstein HC; Lonn EM; Bosch J; Investigators SYOBOTH
Journal
Clinical Nephrology, Vol. 63, No. 3, pp. 181–187
Publisher
Dustri-Verlag Dr. Karl Feistle
Publication Date
March 1, 2005
DOI
10.5414/cnp63181
ISSN
0301-0430